CD38, CD81 and BAFFR combined expression by transitional B cells distinguish active from inactive systemic lupus erythematosus

Clinical and Experimental Medicine

Ana Henriques, Isabel Silva, Luís Inês, M Margarida Souto-Carneiro, Maria Luísa Pais, Helder Trindade, José António Pereira da Silva, Artur Paiva

A. Henriques, I. Silva, M. L. Pais, H. Trindade, A. Paiva
Blood and Transplantation Center of Coimbra, Portuguese Institute of Blood and Transplantation, Portugal

A. Henriques, L. Inês
Faculty of Medicine, University of Coimbra, Coimbra, Portugal

I. Silva, A. Paiva
Coimbra College of Health Technology, Coimbra, Portugal

L. Inês, J. A. P. da Silva
Rheumatology Department, University Hospital of Coimbra, Portugal

L. Inês
Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal

M. M. Souto-Carneiro
ImmunoMetabolic Pharmacology Group, Centre for Neuroscience and Cell Biology, University of Coimbra, Portugal

Corresponding Author
Artur Paiva, PhD
Centro do Sangue e da Transplantação de Coimbra
Quinta da Vinha Moura, São Martinho do Bispo, 3041-861 Coimbra, Portugal
Fax: (+351) 239791071 / Tel: (+351) 239791070
e-mail: artur.paiva@ipst.min-saude.pt
Online Resource 1. Absolute and relative numbers of the different maturation-associated B cell subsets in healthy individuals and patients with systemic lupus erythematosus.

<table>
<thead>
<tr>
<th></th>
<th>NC</th>
<th>ISLE</th>
<th>ASLE</th>
<th>P value NC vs ISLE</th>
<th>P value NC vs ASLE</th>
<th>P value ISLE vs ASLE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>cells/μl</td>
<td>%</td>
<td>cells/μl</td>
<td>%</td>
<td>cells/μl</td>
<td>%</td>
</tr>
<tr>
<td>Lymphocytes*</td>
<td>2166 (5190-1340)</td>
<td>30.5 (17.7-53)</td>
<td>1632 (580-3503)</td>
<td>25 (6-45.9)</td>
<td>837 (220-1630)</td>
<td>11.5 (2.4-48)</td>
</tr>
<tr>
<td>B-lymphocytes*</td>
<td>188 (50-560)</td>
<td>2.9 (0.9-6.8)</td>
<td>172 (36-400)</td>
<td>2.8 (0.7-5.2)</td>
<td>68.3 (9.2-209)</td>
<td>1.1 (0.1-7.2)</td>
</tr>
<tr>
<td>Transitional**</td>
<td>9 (3-37)</td>
<td>4.1 (2.2-9)</td>
<td>15 (1.5-70)</td>
<td>10.1 (1.6-22.5)</td>
<td>5.4 (0.1-25)</td>
<td>6.8 (1-32)</td>
</tr>
<tr>
<td>Naive**</td>
<td>121 (30-356)</td>
<td>60.5 (43.3-74)</td>
<td>113 (17-276)</td>
<td>63.7 (46.4-76)</td>
<td>45 (1.9-166)</td>
<td>63.8 (20-82)</td>
</tr>
<tr>
<td>Memory**</td>
<td>70 (18-204)</td>
<td>34.4 (19-51.4)</td>
<td>37 (8.8-154)</td>
<td>22.5 (10.7-44.1)</td>
<td>10 (0.4-35)</td>
<td>17.5 (4.3-38)</td>
</tr>
<tr>
<td>Plasmablasts**</td>
<td>2.4 (0.6-9)</td>
<td>1.3 (0.3-4.3)</td>
<td>1.4 (0.3-4.9)</td>
<td>0.9 (0.4-3.8)</td>
<td>2.6 (0.03-25)</td>
<td>3 (0.1-46)</td>
</tr>
</tbody>
</table>

Results are expressed as median (range). * Number of cells from total peripheral blood; ** Number of cells from total peripheral blood B cells; NC, healthy individuals, ASLE, active disease, ISLE, inactive disease. P values were determined by Mann Whitney U test; NS, no statistically significant differences observed (P≥0.05).